MADRID (EUROPA PRESS) -The German laboratory BioNTech, responsible together with the American Pfizer for one of the messenger RNA vaccines against covid-19, expects to bill around 5 billion euros this year, a figure substantially below the slightly more than 17 billion euros accounted for in 2022 with the sales of this treatment, according to information from the company.
On the other hand, the pharmaceutical company has revised downward its forecast for R&D spending for the year as a whole, to a range of between 2 thousand and 2 thousand 200 million euros, compared to the previous range of between 2 thousand 400 and 2 thousand 600 million.
In the first six months of the year, the German company’s sales totaled 1,444.7 million euros, 84.9% less, including a 94.7% drop in the second quarter, up to 167.7 million.
In this regard, BioNTech explained that the drop in its quarterly revenue reflects cancellations by its partner, Pfizer, which significantly reduced the company’s share of gross profit in the second quarter and therefore negatively influenced its your income for the three months ended June 30, 2023.
Thus, in the second quarter of the year, BioNTech recorded losses of 190.4 million euros, compared to the net profit of 1,672 million euros recorded between April and June of last year, which in the first six months of the year implied a 94.2% drop in the laboratory’s profits to 311.8 million euros, compared to 5,370.8 million.
“We enter the second half of 2023 in a strong financial position,” said Jens Holstein, BioNTech’s chief financial officer, for whom the covid-19 vaccine market remains highly dynamic and difficult to predict.
“With some uncertainty on the revenue line, we are also watching our expenses carefully by reviewing our cost base while staying focused on meeting our strategic objectives and delivering value to the public and our shareholders,” he added.
